SK Bioscience to supply Novavax COVID-19 vaccine to millions in Korea

By The Science Advisory Board staff writers

February 16, 2021 -- SK Bioscience is set to supply the Korean government with 40 million doses of Novavax's COVID-19 vaccine through a new collaboration and licensing agreement.

The deal with the Korean government covers the manufacturing and commercialization of NVX-CoV2373, expanding on a prior technology transfer agreement. Doses will be available to citizens in the Republic of Korea this year, the companies said in a statement.

Novovax's NVX-CoV2373 is a protein-based vaccine candidate developed with the company's proprietary recombinant nanoparticle technology. The liquid product is stable with refrigeration, which the company says eases distribution.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.